Table 2.
lncRNAs in vascular aging.
| lncRNA | Cell type | Pathway | Effect on senescence | Functional consequences | Reference |
|---|---|---|---|---|---|
| GAS5 (↓) | EPCs | miR-223/NAMPT and PI3K/AKT | — | Inhibited proliferation | [96] |
| SIRT1 AS (↓) | EPCs | miR-22/SIRT1 and PI3K/AKT/ERK | — | Inhibited proliferation and migration | [97, 98] |
| H19 (↓) | HUVECs | STAT3 | — | Inhibited proliferation and angiogenesis, promoted inflammation | [99] |
| MEG3 (↓) | HUVECs | miR-128/Girdin | — | Inhibited platelet phagocytosis | [102] |
| MEG3 (↑) | HUVEC | N/A | + | Inhibited angiogenesis | [103] |
| ASncmtRNA-2 (↑) | HUVECs | miR-4485 and miR-1973, 16S rRNA | + | Promoted apoptosis | [104, 105] |
| ANRIL (↓) | VSMCs | miR-181a/SIRT1 | — | Promoted cell viability | [114] |
| GAS5 (NA) | VSMCs | p53, P300, and β-catenin | N/A | Promoted apoptosis and inhibited proliferation, neointima formation | [116, 117] |
| ES3 (↑) | VSMCs | miR-34c-5p/BMF | + | Promoted calcification | [119] |